In a report released yesterday, Chris Shibutani from Cowen & Co. maintained a Buy rating on Five Prime Therapeutics (FPRX). The company’s shares closed on Friday at $8.40, close to its 52-week low of $7.84.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 0.7% and a 42.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Pieris Pharmaceuticals, and Evelo Biosciences Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Five Prime Therapeutics with a $17 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.55 and a one-year low of $7.84. Currently, Five Prime Therapeutics has an average volume of 300.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150.
